WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558253
CAS#: 128607-22-7
Description: Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulval and vaginal atrophy." The medication was approved by the FDA in February 2013. (Source: http://en.wikipedia.org/wiki/Ospemifene)
Hodoodo Cat#: H558253
Name: Ospemifene
CAS#: 128607-22-7
Chemical Formula: C24H23ClO2
Exact Mass: 378.14
Molecular Weight: 378.896
Elemental Analysis: C, 76.08; H, 6.12; Cl, 9.36; O, 8.45
Synonym: Osphena
IUPAC/Chemical Name: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
InChi Key: LUMKNAVTFCDUIE-VHXPQNKSSA-N
InChi Code: InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
SMILES Code: ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCO)C=C2)\C3=CC=CC=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 378.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Soe LH, Wurz GT, Kao CJ, Degregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health. 2013 Sep 25;5:605-11. doi: 10.2147/IJWH.S39146. Review. PubMed PMID: 24109197; PubMed Central PMCID: PMC3792833.
2: Elkinson S, Yang LP. Ospemifene: first global approval. Drugs. 2013 May;73(6):605-12. doi: 10.1007/s40265-013-0046-y. Review. PubMed PMID: 23605694.
3: McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010 Jun;6(6):773-9. doi: 10.1517/17425255.2010.487483. Review. PubMed PMID: 20429673.
4: Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs. 2009 Jun;18(6):839-49. doi: 10.1517/13543780902953715. Review. PubMed PMID: 19466874.
5: Gennari L. Ospemifene Hormos. Curr Opin Investig Drugs. 2004 Apr;5(4):448-55. Review. PubMed PMID: 15134288.
